|
Category:information only not used for fragrances or flavors
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Soluble in: |
| | water, 0.02019 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
| BOC Sciences |
| For experimental / research use only. |
| Dexanabinol > 95%
Odor: characteristic Use: Dexanabinol is a novel TNF-à inhibitor and an effective neuroprotectant. It might be a useful agent for the treatment of stroke patients, by protecting neuronal lysosomes from nitric oxide (NO)-mediated toxicity. |
Safety Information:
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
|
Not determined
|
| Dermal Toxicity: |
|
Not determined
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | information only not used for fragrances or flavors |
| Recommendation for dexanabinol usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for dexanabinol flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
| EPI System: View |
| ClinicalTrials.gov:search |
| AIDS Citations:Search |
| Cancer Citations:Search |
| Toxicology Citations:Search |
| EPA ACToR:Toxicology Data |
| EPA Substance Registry Services (SRS):Registry |
| Laboratory Chemical Safety Summary :107778 |
| National Institute of Allergy and Infectious Diseases:Data |
| (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol |
| Chemidplus:0112924455 |
References:
| | (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 107778 |
| Pubchem (cas): | 112924-45-5 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| (6aS-trans)-3-(1,1- | dimethyl heptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo(b,d)pyran-9-methanol | | 1,1- | dimethyl heptyl-11-hydroxytetrahydrocannabinol | | 1,1- | dimethylheptyl-11-hydroxytetrahydrocannabinol | | | HU 211 | | 11- | hydroxy-delta(8)-tetrahydrocannabinol-dimethylheptyl | | (6aS,10aS)-9-( | hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | | | sinnabidiol |
Articles:
| PubMed:Targeting the Endocannabinoid/CB1 Receptor System For Treating Major Depression Through Antidepressant Activities of Curcumin and Dexanabinol-Loaded Solid Lipid Nanoparticles. |
| PubMed:A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury. |
| PubMed:Use of magnesium in traumatic brain injury. |
| PubMed:Effect of abdominal surgery on the intestinal absorption of lipophilic drugs: possible role of the lymphatic transport. |
| PubMed:Importance of screening logs in clinical trials for severe traumatic brain injury. |
| PubMed:The protective effect of dexanabinol (HU-211) on nitric oxide and cysteine protease-mediated neuronal death in focal cerebral ischemia. |
| PubMed:Peroxisome proliferator-activated receptors: "key" regulators of neuroinflammation after traumatic brain injury. |
| PubMed:Dexanabinol prevents development of vasospasm in the rat femoral artery model. |
| PubMed:Observer variation in the assessment of outcome in traumatic brain injury: experience from a multicenter, international randomized clinical trial. |
| PubMed:Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. |
| PubMed:[The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans]. |
| PubMed:Gateways to clinical trials. |
| PubMed:Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. |
| PubMed:Gateways to clinical trials. |
| PubMed:Gateways to clinical trials. |
| PubMed:Recent advances in the development of multifactorial therapies for the treatment of traumatic brain injury. |
| PubMed:Cognitive deficits following coronary artery bypass grafting: prevalence, prognosis, and therapeutic strategies. |
| PubMed:The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). |
| PubMed:Synergism between tumor necrosis factor-alpha and H2O2 enhances cell damage in rat PC12 cells. |
| PubMed:[New therapies for intracranial hypertension]. |
| PubMed:Gateways to clinical trials. |
| PubMed:Dexanabinol: a novel cannabinoid with neuroprotective properties. |
| PubMed:Combination of dexanabinol and tempol in focal cerebral ischemia: is there a ceiling effect? |
| PubMed:Dexanabinol: dexanabinone, HU 211, PA 50211, PRS 211007, sinnabidol. |
| PubMed:Therapeutic potential of cannabinoids in CNS disease. |
| PubMed:Promising strategies to minimize secondary brain injury after head trauma. |
| PubMed:Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury. |
| PubMed:Dexanabinol as a treatment for traumatic brain injury: will another therapeutic promise be broken? |
| PubMed:Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. |
| PubMed:The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. |
| PubMed:Attempts of ranking in a series of synthetic nonpsychotropic cannabinoids. |
| PubMed:Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. |
| PubMed:Dexanabinol Pharmos. |
| PubMed:Nonpsychotropic synthetic cannabinoids. |
| PubMed:Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoid. |
| PubMed:Water-soluble combinations of dexanabinol: prodrugs and analogs. |
| PubMed:Neuroprotective effects of HU-211 on brain damage resulting from soman-induced seizures. |
| PubMed:Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. |
| PubMed:In vitro and in vivo study of water-soluble prodrugs of dexanabinol. |
| PubMed:Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. |
| PubMed:Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system. |
| PubMed:Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. |
| PubMed:Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. |
| PubMed:Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. |
| PubMed:Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility. |
| PubMed:Derivatives of Dexanabinol. I. Water-soluble salts of glycinate esters. |
| PubMed:Development of HU-211 as a neuroprotectant for ischemic brain damage. |
|
3D/inchi